Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead

CURIS INC

• Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.
• No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.
• Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.
• Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.
• TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.